Table 6: **RT**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 169 | 1E8 | RT(65–73) | RT(65–73) | KKDSTKWRK | no | Vaccine | murine(IgG1) |

***Vaccine:*** *Vector/type:* recombinant protein *HIV component:* RT *Stimulatory Agents:* nitrocellulose

**References:** [Wu (1993), Gu (1996)]

- 1E8: Inhibits RT activity, binding site overlaps with two AZT resistance mutations [Wu (1993)]
- 1E8: Significantly inhibits DNA polymerase activity of RT by hindering binding of dNTPs – additive or synergistic RT inhibition with nevirapine and delavirdine [Gu (1996)]

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 170 | 1.152 B3 | RT(294–302) | RT(294–302) | PLTEEAELE | no | Vaccine | murine(IgG1) |

***Vaccine:*** *Vector/type:* recombinant protein *HIV component:* RT

**References:** [Orvell (1991)]

- 1.152 B3: Weakly positive by immunofluorescence – binding inhibits RT enzymatic activity [Orvell (1991)]

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 171 | 1.158 E2 | RT(294–302) | RT(294–302) | PLTEEAELE | no | Vaccine | murine(IgG1) |

***Vaccine:*** *Vector/type:* recombinant protein *HIV component:* RT

**References:** [Orvell (1991)]

- 1.158 E2: Negative by immunofluorescence – binding inhibits RT enzymatic activity [Orvell (1991)]

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 172 | 31D6 | RT(294–318) | RT(294–319) | PLTEEAELELAENREILKEPVHGVY | no | Vaccine | murine(IgG1) |

***Vaccine:*** *Vector/type: E. coli* Trp fusion protein *HIV component:* RT

**References:** [Szilvay (1992)]

- 31D6: Strong inhibitor of RT, > 50% inhibition [Szilvay (1992)]

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 173 | 31G8 | RT(294–318) | RT(294–319) | PLTEEAELELAENREILKEPVHGVY | no | Vaccine | murine(IgG1) |

***Vaccine:*** *Vector/type: E. coli* Trp fusion protein *HIV component:* RT

**References:** [Szilvay (1992)]

- 31G8: Weak inhibitor of RT, reactive by immunofluorescence [Szilvay (1992)]

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 174 | 32E7 | RT(294–318) | RT(294–319) | PLTEEAELELAENREILKEPVHGVY | no | Vaccine | murine(IgG1) |

***Vaccine:*** *Vector/type: E. coli* Trp fusion protein *HIV component:* RT

**References:** [Szilvay (1992)]

- 32E7: Weak inhibitor of RT, reactive by immunofluorescence [Szilvay (1992)]

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 175 | 33D5 | RT(294–318) | RT(294–319) | PLTEEAELELAENREILKEPVHGVY | no | Vaccine | murine(IgG1) |

***Vaccine:*** *Vector/type: E. coli* Trp fusion protein *HIV component:* RT

**References:** [Szilvay (1992)]

- 33D5: Weak inhibitor of RT, reactive by immunofluorescence [Szilvay (1992)]

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 176 | 5B2 | RT(294–318) | RT(294–319) | PLTEEAELELAENREILKEPVHGVY | no | Vaccine | murine(IgG1) |

***Vaccine:*** *Vector/type: E. coli* Trp fusion protein *HIV component:* RT

**References:** [Szilvay (1992)]

- 5B2: There is an RT specific Ab [Szilvay (1992)] and a gp41 specific Ab [Tian (2001)] both called 5B2
- 5B2: Weak inhibitor of RT, reactive by immunofluorescence [Szilvay (1992)]
- 5B2: UK Medical Research Council AIDS reagent: ARP3018

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 177 | polyclonal | RT(295–304) | RT(295–304 PV22) | LTEEAELELA | no | HIV-1 infection | human(IgG) |

**References:** [Grimison & Laurence(1995)]

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 178 | 1.153 G10 | RT(350–354) | RT(350–354) | KTGKY | no | Vaccine | murine(IgG1) |

***Vaccine:*** *Vector/type:* recombinant protein *HIV component:* RT

**References:** [Orvell (1991)]

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 179 | RTMAb8 | RT(376–383) | RT(532–539) | TTESIVIW | no | Vaccine | murine(IgG) |

***Vaccine:*** *Vector/type:* recombinant protein *HIV component:* RT

**References:** [Tisdale (1988), Ferns (1991)]

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 180 | 1D4A3 | RT(384–387) | RT(540–543) | GKIP | no | Vaccine | murine(IgG) |

***Vaccine:*** *Vector/type:* recombinant protein *HIV component:* RT

**References:** [Ferns (1991)]

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 181 | RT6H | RT(384–387) | RT(540–543) | | no | Vaccine | murine(IgG) |

***Vaccine:*** *Vector/type:* recombinant protein *HIV component:* RT

**References:** [Ferns (1991)]

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 182 | 1.160 B3 | RT(442–450) | RT(442–450) | VDGAANRET | no | Vaccine | murine(IgG1) |

***Vaccine:*** *Vector/type:* recombinant protein *HIV component:* RT

**References:** [Orvell (1991)]

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 183 | polyclonal | RT(521–531) | RT(521–531 PV22) | IIEQLIKKEKV | no | HIV-1 infection | human(IgG) |

**References:** [Grimison & Laurence(1995)]

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 184 | C2003 | RT(536–549) | RT(703–716 BH10) | VPAHKGIGGNEQVD | no | Vaccine | rabbit(IgG) |

***Vaccine:*** *Vector/type:* peptide *Strain:* BH10

**References:** [DeVico (1991)]

- C2003: Inhibits polymerase activity from a variety of retroviruses – RT protected from inhibition by preincubation with template primer [DeVico (1991)]

---

185 6B9 RT( ) RT(155–250) Vaccine murine(IgG)

***Vaccine:*** *Vector/type:* vaccinia *Strain:* HXB2 *HIV component:* RT

**Ab type:** palm domain **References:** [Chiba (1996), Chiba (1997), Ohba (2001)]

- 6B9: In contrast to MAb 7C4, which binds to the thumb region of RT, 6B9 binds to the palm subdomain and does not inhibit RT activity [Chiba (1996)]

---

186 5F RT( ) RT(252–335) Vaccine murine( )

***Vaccine:*** *Vector/type:* vaccinia *Strain:* HXB2 *HIV component:* RT

**Ab type:** thumb domain **References:** [Ohba (2001)]

- 5F: BALB/c mice were vaccinated with vaccinia carrying RT and a phage display library was produced and panned with RT – Fabs 5F and 5G were cloned, both recognizing an immunodominant neutralizing RT epitope in the region of the template primer-binding site in the thumb domain also recognized by MAb 7C4 – sequencing revealed the heavy chains and light chains of 7C4, 5G and 7C4 are related [Ohba (2001)]

---

187 5G RT( ) RT(252–335) Vaccine murine( )

***Vaccine:*** *Vector/type:* vaccinia *Strain:* HXB2 *HIV component:* RT

**Ab type:** thumb domain **References:** [Ohba (2001)]

- 5G: BALB/c mice were vaccinated with vaccinia carrying RT and a phage display library was produced and panned with RT – Fabs 5F and 5G were cloned, both recognizing an immunodominant neutralizing RT epitope in the region of the template primer-binding site in the thumb domain also recognized by MAb 7C4 – sequencing revealed the heavy chains and light chains of 7C4, 5G and 7C4 are related [Ohba (2001)]

---

188 7C4 RT( ) RT(252–335) Vaccine murine(IgG2a)

***Vaccine:*** *Vector/type:* vaccinia *Strain:* HXB2 *HIV component:* RT

**Ab type:** thumb domain **References:** [Chiba (1996), Chiba (1997), Ohba (2001)]

- 7C4: 7C4 was produced from a hybridoma cell line derived from a BALB/c mouse repeatedly immunized with RT in a vaccinia construct, and was found to inhibit RT through binding to the template primer-binding site, a possible target for RT inhibitors [Chiba (1996)]
- 7C4: 7C4 inhibits RT from HIV-1 strains IIIB, Bru, and IMS-1 but not HIV-2 strains GH-1 and LAV-2, SIV MAC, nor SIV MND [Chiba (1997)]
- 7C4: Fabs 5F and 5G both recognize the same immunodominant neutralizing RT epitope in the region of the template primer-binding site in the thumb domain recognized by MAb 7C4 – sequencing revealed the heavy chains and light chains of 7C4, 5G and 7C4 are related [Ohba (2001)]

---